Skip to main content
Monday, November 16, 2026Nov 16

Pfizer net plunges 38 pct., misses Street 3Q forecasts

FILE - In this Monday, Nov. 23, 2015, file photo, a woman passes Pfizer's world headquarters, in New York. Pfizer reports financial results Tuesday, Nov. 1, 2016. (AP Photo/Mark Lennihan, File)
FILE - In this Monday, Nov. 23, 2015, file photo, a woman passes Pfizer's world headquarters, in New York. Pfizer reports financial results Tuesday, Nov. 1, 2016. (AP Photo/Mark Lennihan, File)

Drugmaker Pfizer’s third-quarter profit plunged 38 percent as higher spending and a slew of acquisition-related charges more than offset higher sales, sending its shares down before the stock market opened.

The mediocre results missed Wall Street expectations, Pfizer lowered the top end of its 2016 profit forecast and it said it was scrapping development of a closely watched experimental cholesterol drug, partly due to reduced sales expectations.

Coming after Pfizer Inc.’s Sept. 26 announcement that it won’t split into two companies to accelerate growth – a move some investors and analysts had hoped would boost Pfizer’s lagging stock – Tuesday’s disappointed investors.

In early-morning trading, shares fell 50 cents, or 1.6 percent, to $31.20.

“Some investors feel the company has careened from strategy to strategy over the past few years,” said Erik Gordon, a professor and pharmaceuticals analyst at University of Michigan’s Ross School of Business.